The Pharma Data

DECEMBER 23, 2020

COVAXX is currently completing a Phase 1 clinical trial of UB-612 in Taiwan and will begin Phase 2/3 clinical trials in Asia, Latin America and the U.S. This agreement is in addition to the recently announced advanced purchase commitments of more than 140 million doses of COVAXX’s UB-612 vaccine, totaling over $2.8 About COVAXX.

Vaccine 52

Vaccine Vaccination Manufacturing Antibody 52

The Pharma Data

DECEMBER 23, 2020

24, 2020 /PRNewswire/ — COVAXX’s UB-612 is the first multitope, synthetic peptide-based COVID-19 vaccine candidate in clinical trials and it utilizes normal refrigeration (no freezing required) for distribution. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate. .

Vaccine 52

Vaccine Vaccination Development Manufacturing 52

XTalks

AUGUST 2, 2023

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. Toujeo generated Sanofi €1.12 Additional revenue came from the acquisition of Alexion Pharmaceuticals in July 2021. billion ($1.17 billion USD) in revenue in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98